In contrast, previous studies showed that treatment with roxadustat markedly improved hypertension and organ injury in an angiotensin II model of hypertension, possibly through stabilization of HIF1α and subsequent targeting of endothelial nitric oxide synthase (eNOS), AGTR1, AGTR2, and oxidative stress [56]. The gene discussed is AGTR2; the disease is hypertensive disorder.